Juvenile Myelomonocytic Leukemia Clinical Trials
3 recruiting trials for Juvenile Myelomonocytic Leukemia. Eligibility criteria explained in plain English.
TrialFinderData lists 3 Juvenile Myelomonocytic Leukemia clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (3 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Masonic Cancer Center, University of Minnesota (2), University of Florida (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Miltenyi CliniMACS Prodigy ® system (device, 1 trial), followed by HSCT with TBI Regimen, HSCT with Non-TBI Regimen.
Track Juvenile Myelomonocytic Leukemia trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute...
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or,...
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults...
Explore Other Conditions
Frequently Asked Questions
There are currently 3 clinical trials for Juvenile Myelomonocytic Leukemia, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Juvenile Myelomonocytic Leukemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Juvenile Myelomonocytic Leukemia, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.